Organoid models in oncology: advancing precision cancer therapy and vaccine development

References

1. 1.↵
   2. Xu H,
   3. Lyu X,
   4. Yi M,
   5. Zhao W,
   6. Song Y,
   7. Wu K.

   Organoid technology and applications in cancer research. J Hematol Oncol. 2018; 11: 116.

   OpenUrlPubMed
2. 2.↵
   2. Tong Y,
   3. Cheng PSW,
   4. Or CS,
   5. Yue SSK,
   6. Siu HC,
   7. Ho SL, et al.

   Escape from cell-cell and cell-matrix adhesion dependence underscores disease progression in gastric cancer organoid models. Gut. 2023; 72: 42–255.

   OpenUrl
3. 3.
   2. Farin HF,
   3. Mosa MH,
   4. Ndreshkjana B,
   5. Grebbin BM,
   6. Ritter B,
   7. Menche C, et al.

   Colorectal cancer organoid-stroma biobank allows subtype-specific assessment of individualized therapy responses. Cancer Discov. 2023; 13: 2192–211.

   OpenUrlCrossRefPubMed
4. 4.
   2. Pan Y,
   3. Han H,
   4. Hu H,
   5. Wang H,
   6. Song Y,
   7. Hao Y, et al.

   KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition. Cancer Cell. 2023; 41: 88–105.e8.

   OpenUrlCrossRefPubMed
5. 5.↵
   2. Duan X,
   3. Zhang T,
   4. Feng L,
   5. de Silva N,
   6. Greenspun B,
   7. Wang X, et al.

   A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS. Cell Stem Cell. 2024; 31: 71–88.e8.

   OpenUrlPubMed
6. 6.↵
   2. Wang X,
   3. Wen S,
   4. Du X,
   5. Zhang Y,
   6. Yang X,
   7. Zou R, et al.

   SAA suppresses α-PD-1 induced anti-tumor immunity by driving T_H2 polarization in lung adenocarcinoma. Cell Death Dis. 2023; 14: 718.

   OpenUrlPubMed
7. 7.↵
   2. Llovet JM,
   3. Pinyol R,
   4. Yarchoan M,
   5. Singal AG,
   6. Marron TU,
   7. Schwartz M, et al.

   Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. Nat Rev Clin Oncol. 2024; 21: 294–311.

   OpenUrlCrossRefPubMed
8. 8.↵
   2. Cantini L,
   3. Trapani D,
   4. Guidi L,
   5. Boscolo Bielo L,
   6. Scafetta R,
   7. Koziej M, et al.

   Neoadjuvant therapy in hormone receptor-positive/HER2-negative breast cancer. Cancer Treat Rev. 2024; 123: 102669.
9. 9.↵
   2. Patel SP,
   3. Othus M,
   4. Chen Y,
   5. Wright GP Jr.,
   6. Yost KJ,
   7. Hyngstrom JR, et al.

   Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med. 2023; 388: 813–23.

   OpenUrlCrossRefPubMed
10. 10.↵
    2. Seppälä TT,
    3. Zimmerman JW,
    4. Sereni E,
    5. Plenker D,
    6. Suri R,
    7. Rozich N, et al.

    Patient-derived organoid pharmacotyping is a clinically tractable strategy for precision medicine in pancreatic cancer. Ann Surg. 2020; 272: 427–35.

    OpenUrlCrossRefPubMed
11. 11.↵
    2. Jiang L,
    3. Qin J,
    4. Dai Y,
    5. Zhao S,
    6. Zhan Q,
    7. Cui P, et al.

    Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma. Nat Med. 2024; 30: 749–61.

    OpenUrlCrossRefPubMed
12. 12.↵
    2. Nakahara Y,
    3. Kouro T,
    4. Igarashi Y,
    5. Kawahara M,
    6. Sasada T.

    Prospects for a personalized peptide vaccine against lung cancer. Expert Rev Vaccines. 2019; 18: 703–9.

    OpenUrlPubMed
13. 13.↵
    2. Hu B,
    3. Wang R,
    4. Wu D,
    5. Long R,
    6. Fan J,
    7. Hu Z, et al.

    A promising new model: establishment of patient-derived organoid models covering HPV-related cervical pre-cancerous lesions and their cancers. Adv Sci (Weinh). 2024; 11: e2302340.
14. 14.↵
    2. Cekanova M,
    3. Rathore K.

    Animal models and therapeutic molecular targets of cancer: utility and limitations. Drug Des Devel Ther. 2014; 8: 1911–21.

    OpenUrlCrossRefPubMed
15. 15.↵
    2. Yan N,
    3. Xie W,
    4. Wang D,
    5. Fang Q,
    6. Guo J,
    7. Chen Y, et al.

    Single-cell transcriptomic analysis reveals tumor cell heterogeneity and immune microenvironment features of pituitary neuroendocrine tumors. Genome Med. 2024; 16: 2.

    OpenUrlPubMed
16. 16.↵
    2. Sharma MP,
    3. Shukla S,
    4. Misra G.

    Recent advances in breast cancer cell line research. Int J Cancer. 2024; 154: 1683–93.

    OpenUrlPubMed
17. 17.↵
    2. Yamada KM,
    3. Cukierman E.

    Modeling tissue morphogenesis and cancer in 3D. Cell. 2007; 130: 601–10.

    OpenUrlCrossRefPubMedWeb of Science
18. 18.↵
    2. Crouchet E,
    3. Almeida N,
    4. Durand SC,
    5. Parnot M,
    6. Oudot MA,
    7. Giannone F, et al.

    A patient-derived HCC spheroid system to model the tumor microenvironment and treatment response. JHEP Rep. 2025; 7: 101252.
19. 19.↵
    2. Nath S,
    3. Devi GR.

    Three-dimensional culture systems in cancer research: focus on tumor spheroid model. Pharmacol Ther. 2016; 163: 94–108.

    OpenUrlCrossRefPubMed
20. 20.↵
    2. Obakan Yerlikaya P,
    3. Adacan K,
    4. Karatug Kacar A,
    5. Coker Gurkan A,
    6. Arisan ED.

    Epibrassinolide impaired colon tumor progression and induced autophagy in SCID mouse xenograft model via acting on cell cycle progression without affecting endoplasmic reticulum stress observed in vitro. Int J Biochem Cell Biol. 2023; 155: 106360.
21. 21.↵
    2. Zhou W,
    3. Fan T,
    4. Yan Y,
    5. Chen Y,
    6. Ma X,
    7. Yang T, et al.

    A manganese-oxide nano-rambutan as the intrinsic modifier for hypericin delivery and triple-negative breast cancer treatment. Int J Pharm. 2024; 666: 124824.
22. 22.↵
    2. Wang J,
    3. Chen Y,
    4. Xu Y,
    5. Zhang J,
    6. Yang S,
    7. Zhou Y, et al.

    DNASE1L3-mediated PANoptosis enhances the efficacy of combination therapy for advanced hepatocellular carcinoma. Theranostics. 2024; 14: 6798–817.

    OpenUrlPubMed
23. 23.↵
    2. Cao R,
    3. Li R,
    4. Lai C,
    5. Shi H,
    6. Liu H,
    7. Cheng Z.

    Development of a novel HER2-targeted peptide probe for dual-modal imaging of tumors. J Med Chem. 2023; 66: 7523–33.

    OpenUrlPubMed
24. 24.↵
    2. Vasseur D,
    3. Bigot L,
    4. Beshiri K,
    5. Flórez-Arango J,
    6. Facchinetti F,
    7. Hollebecque A, et al.

    Deciphering resistance mechanisms in cancer: final report of MATCH-R study with a focus on molecular drivers and PDX development. Mol Cancer. 2024; 23: 221.

    OpenUrlPubMed
25. 25.↵
    2. Abdolahi S,
    3. Ghazvinian Z,
    4. Muhammadnejad S,
    5. Saleh M,
    6. Asadzadeh Aghdaei H,
    7. Baghaei K.

    Patient-derived xenograft (PDX) models, applications and challenges in cancer research. J Transl Med. 2022; 20: 206.

    OpenUrlCrossRefPubMed
26. 26.↵
    2. Sell T,
    3. Klotz C,
    4. Fischer MM,
    5. Astaburuaga-García R,
    6. Krug S,
    7. Drost J, et al.

    Oncogenic signaling is coupled to colorectal cancer cell differentiation state. J Cell Biol. 2023; 222: e202204001.
27. 27.↵
    2. Ou L,
    3. Liu S,
    4. Wang H,
    5. Guo Y,
    6. Guan L,
    7. Shen L, et al.

    Patient-derived melanoma organoid models facilitate the assessment of immunotherapies. EBioMedicine. 2023; 92: 104614.
28. 28.↵
    2. Jacob F,
    3. Salinas RD,
    4. Zhang DY,
    5. Nguyen PTT,
    6. Schnoll JG,
    7. Wong SZH, et al.

    A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity. Cell. 2020; 180: 188-204.e22.

    OpenUrlCrossRefPubMed
29. 29.↵
    2. Xiao Y,
    3. Ma D,
    4. Yang YS,
    5. Yang F,
    6. Ding JH,
    7. Gong Y, et al.

    Comprehensive metabolomics expands precision medicine for triple-negative breast cancer. Cell Res. 2022; 32: 477–90.

    OpenUrlCrossRefPubMed
30. 30.↵
    2. Zu M,
    3. Hao X,
    4. Ning J,
    5. Zhou X,
    6. Gong Y,
    7. Lang Y, et al.

    Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing. Biomed Pharmacother. 2023; 163: 114751.
31. 31.↵
    2. Mahadevan KK,
    3. McAndrews KM,
    4. LeBleu VS,
    5. Yang S,
    6. Lyu H,
    7. Li B, et al.

    KRAS^G12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8⁺ T cells. Cancer Cell. 2023; 41: 1606-20.e8.

    OpenUrlCrossRefPubMed
32. 32.↵
    2. Zhou G,
    3. Lieshout R,
    4. van Tienderen GS,
    5. de Ruiter V,
    6. van Royen ME,
    7. Boor PPC, et al.

    Modelling immune cytotoxicity for cholangiocarcinoma with tumour-derived organoids and effector T cells. Br J Cancer. 2022; 127: 649–60.

    OpenUrlCrossRefPubMed
33. 33.↵
    2. Dijkstra KK,
    3. Cattaneo CM,
    4. Weeber F,
    5. Chalabi M,
    6. van de Haar J,
    7. Fanchi LF, et al.

    Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids. Cell. 2018; 174: 1586-98.e12.

    OpenUrlCrossRefPubMed
34. 34.↵
    2. Wang X,
    3. Fang Y,
    4. Liang W,
    5. Wong CC,
    6. Qin H,
    7. Gao Y, et al.

    Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer. Cancer Cell. 2024; 42: 1729-46.e8.

    OpenUrlCrossRefPubMed
35. 35.↵
    2. Jiang S,
    3. Deng T,
    4. Cheng H,
    5. Liu W,
    6. Shi D,
    7. Yuan J, et al.

    Macrophage-organoid co-culture model for identifying treatment strategies against macrophage-related gemcitabine resistance. J Exp Clin Cancer Res. 2023; 42: 199.

    OpenUrlPubMed
36. 36.↵
    2. Zou Z,
    3. Lin Z,
    4. Wu C,
    5. Tan J,
    6. Zhang J,
    7. Peng Y, et al.

    Micro-engineered organoid-on-a-chip based on mesenchymal stromal cells to predict immunotherapy responses of HCC patients. Adv Sci (Weinh). 2023; 10: e2302640.
37. 37.↵
    2. Hu Y,
    3. Sui X,
    4. Song F,
    5. Li Y,
    6. Li K,
    7. Chen Z, et al.

    Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week. Nat Commun. 2021; 12: 2581.

    OpenUrlCrossRefPubMed
38. 38.↵
    2. Chen M,
    3. Shan H,
    4. Tao Q,
    5. Hu R,
    6. Sun Q,
    7. Zheng M, et al.

    Mimicking tumor metastasis using a transwell-integrated organoids-on-a-chip platform. Small. 2024; 20: e2308525.
39. 39.↵
    2. Zhang J,
    3. Tavakoli H,
    4. Ma L,
    5. Li X,
    6. Han L,
    7. Li X.

    Immunotherapy discovery on tumor organoid-on-a-chip platforms that recapitulate the tumor microenvironment. Adv Drug Deliv Rev. 2022; 187: 114365.
40. 40.↵
    2. Qureshi AA,
    3. Wehrle CJ,
    4. Ferreira-Gonzalez S,
    5. Jiao C,
    6. Hong H,
    7. Dadgar N, et al.

    Tumor organoids for primary liver cancers: a systematic review of current applications in diagnostics, disease modeling, and drug screening. JHEP Rep. 2024; 6: 101164.
41. 41.↵
    2. Ji S,
    3. Feng L,
    4. Fu Z,
    5. Wu G,
    6. Wu Y,
    7. Lin Y, et al.

    Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology. Sci Transl Med. 2023; 15: eadg3358.
42. 42.↵
    2. Zhang Y,
    3. Lian X,
    4. Xu H,
    5. Zhu S,
    6. Zhang H,
    7. Ni Z, et al.

    Orgxenomics: an integrated proteomic knowledge base for patient-derived organoid and xenograft. Nucleic Acids Res. 2025; 53: D504–15.

    OpenUrlPubMed
43. 43.↵
    2. Ishikawa T,
    3. Ogawa T,
    4. Nakanome A,
    5. Yamauchi Y,
    6. Usubuchi H,
    7. Shiihara M, et al.

    Whole exome sequencing and establishment of an organoid culture of the carcinoma showing thymus-like differentiation (CASTLE) of the parotid gland. Virchows Arch. 2021; 478: 1149–59.

    OpenUrlPubMed
44. 44.↵
    2. Zhang CJ,
    3. Meyer SR,
    4. O’Meara MJ,
    5. Huang S,
    6. Capeling MM,
    7. Ferrer-Torres D, et al.

    A human liver organoid screening platform for DILI risk prediction. J Hepatol. 2023; 78: 998–1006.

    OpenUrlPubMed
45. 45.↵
    2. Fazio M,
    3. Ablain J,
    4. Chuan Y,
    5. Langenau DM,
    6. Zon LI.

    Zebrafish patient avatars in cancer biology and precision cancer therapy. Nat Rev Cancer. 2020; 20: 263–73.

    OpenUrlCrossRefPubMed
46. 46.↵
    2. Ruta V,
    3. Naro C,
    4. Pieraccioli M,
    5. Leccese A,
    6. Archibugi L,
    7. Cesari E, et al.

    An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic cancer. Cell Rep Med. 2024; 5: 101411.
47. 47.↵
    2. Kumar V,
    3. Ramnarayanan K,
    4. Sundar R,
    5. Padmanabhan N,
    6. Srivastava S,
    7. Koiwa M, et al.

    Single-cell atlas of lineage states, tumor microenvironment, and subtype-specific expression programs in gastric cancer. Cancer Discov. 2022; 12: 670–91.

    OpenUrlCrossRefPubMed
48. 48.↵
    2. Song H,
    3. Weinstein HNW,
    4. Allegakoen P,
    5. Wadsworth MH 2nd.,
    6. Xie J,
    7. Yang H, et al.

    Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states. Nat Commun. 2022; 13: 141.

    OpenUrlCrossRefPubMed
49. 49.↵
    2. Wang R,
    3. Li J,
    4. Zhou X,
    5. Mao Y,
    6. Wang W,
    7. Gao S, et al.

    Single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer tumors. Genome Med. 2022; 14: 93.

    OpenUrlCrossRefPubMed
50. 50.↵
    2. Wang X,
    3. Dai Z,
    4. Lin X,
    5. Zou X,
    6. Wang R,
    7. Tasiheng Y, et al.

    Antigen/HLA-agnostic strategies for characterizing tumor-responsive t cell receptors in PDAC patients via single-cell sequencing and autologous organoid application. Cancer Lett. 2024; 588: 216741.
51. 51.
    2. Mo S,
    3. Tang P,
    4. Luo W,
    5. Zhang L,
    6. Li Y,
    7. Hu X, et al.

    Patient-derived organoids from colorectal cancer with paired liver metastasis reveal tumor heterogeneity and predict response to chemotherapy. Adv Sci (Weinh). 2022; 9: e2204097.
52. 52.
    2. Gao L,
    3. Wei Z,
    4. Ying F,
    5. Huang L,
    6. Zhang J,
    7. Sun S, et al.

    Glutamine metabolism prognostic index predicts tumour microenvironment characteristics and therapeutic efficacy in ovarian cancer. J Cell Mol Med. 2024; 28: e18198.
53. 53.
    2. Fendler A,
    3. Bauer D,
    4. Busch J,
    5. Jung K,
    6. Wulf-Goldenberg A,
    7. Kunz S, et al.

    Inhibiting WNT and NOTCH in renal cancer stem cells and the implications for human patients. Nat Commun. 2020; 11: 929.

    OpenUrlCrossRefPubMed
54. 54.↵
    2. Braun FK,
    3. Rothhammer-Hampl T,
    4. Lorenz J,
    5. Pohl S,
    6. Menevse AN,
    7. Vollmann-Zwerenz A, et al.

    Scaffold-based (Matrigel™) 3D culture technique of glioblastoma recovers a patient-like immunosuppressive phenotype. Cells. 2023; 12: 1856.

    OpenUrl
55. 55.↵
    2. Cheng J,
    3. Xie W,
    4. Chen Y,
    5. Sun Y,
    6. Gong L,
    7. Wang H, et al.

    Drug resistance mechanisms in dopamine agonist-resistant prolactin pituitary neuroendocrine tumors and exploration for new drugs. Drug Resist Updat. 2024; 73: 101056.
56. 56.↵
    2. Zhao Y,
    3. Li ZX,
    4. Zhu YJ,
    5. Fu J,
    6. Zhao XF,
    7. Zhang YN, et al.

    Single-cell transcriptome analysis uncovers intratumoral heterogeneity and underlying mechanisms for drug resistance in hepatobiliary tumor organoids. Adv Sci (Weinh). 2021; 8: e2003897.
57. 57.↵
    2. Schuth S,
    3. Le Blanc S,
    4. Krieger TG,
    5. Jabs J,
    6. Schenk M,
    7. Giese NA, et al.

    Patient-specific modeling of stroma-mediated chemoresistance of pancreatic cancer using a three-dimensional organoid-fibroblast co-culture system. J Exp Clin Cancer Res. 2022; 41: 312.

    OpenUrlPubMed
58. 58.↵
    2. Lin L,
    3. DeMartino J,
    4. Wang D,
    5. van Son GJF,
    6. van der Linden R,
    7. Begthel H, et al.

    Unbiased transcription factor CRISPR screen identifies ZNF800 as master repressor of enteroendocrine differentiation. Science. 2023; 382: 451–8.

    OpenUrlCrossRefPubMed
59. 59.↵
    2. Ding Z,
    3. Pan Y,
    4. Shang T,
    5. Jiang T,
    6. Lin Y,
    7. Yang C, et al.

    Uri alleviates tyrosine kinase inhibitors-induced ferroptosis by reprogramming lipid metabolism in p53 wild-type liver cancers. Nat Commun. 2023; 14: 6269.

    OpenUrlPubMed
60. 60.↵
    2. Wang SQ,
    3. Chen JJ,
    4. Jiang Y,
    5. Lei ZN,
    6. Ruan YC,
    7. Pan Y, et al.

    Targeting GSTP1 as therapeutic strategy against lung adenocarcinoma stemness and resistance to tyrosine kinase inhibitors. Adv Sci (Weinh). 2023; 10: e2205262.
61. 61.↵
    2. Yan R,
    3. Fan X,
    4. Xiao Z,
    5. Liu H,
    6. Huang X,
    7. Liu J, et al.

    Inhibition of DCLK1 sensitizes resistant lung adenocarcinomas to EGFR-TKI through suppression of Wnt/β-catenin activity and cancer stemness. Cancer Lett. 2022; 531: 83–97.

    OpenUrlPubMed
62. 62.↵
    2. Jin Z,
    3. Lu Y,
    4. Wu X,
    5. Pan T,
    6. Yu Z,
    7. Hou J, et al.

    The cross-talk between tumor cells and activated fibroblasts mediated by lactate/BDNF/TrkB signaling promotes acquired resistance to anlotinib in human gastric cancer. Redox Biol. 2021; 46: 102076.
63. 63.↵
    2. Wang Y,
    3. Jiang T,
    4. Qin Z,
    5. Jiang J,
    6. Wang Q,
    7. Yang S, et al.

    HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib. Ann Oncol. 2019; 30: 447–55.

    OpenUrlCrossRefPubMed
64. 64.↵
    2. Lee EJ,
    3. Oh SY,
    4. Lee YW,
    5. Kim JY,
    6. Kim MJ,
    7. Kim TH, et al.

    Discovery of a novel potent EGFR inhibitor against EGFR activating mutations and on-target resistance in NSCLC. Clin Cancer Res. 2024; 30: 1582–94.

    OpenUrlPubMed
65. 65.↵
    2. Kim SY,
    3. Kim SM,
    4. Lim S,
    5. Lee JY,
    6. Choi SJ,
    7. Yang SD, et al.

    Modeling clinical responses to targeted therapies by patient-derived organoids of advanced lung adenocarcinoma. Clin Cancer Res. 2021; 27: 4397–409.

    OpenUrlAbstract/FREE Full Text
66. 66.↵
    2. Lee SY,
    3. Cho HJ,
    4. Choi J,
    5. Ku B,
    6. Moon SW,
    7. Moon MH, et al.

    Cancer organoid-based diagnosis reactivity prediction (CODRP) index-based anticancer drug sensitivity test in ALK-rearrangement positive non-small cell lung cancer (NSCLC). J Exp Clin Cancer Res. 2023; 42: 309.

    OpenUrlPubMed
67. 67.↵
    2. Lee SH,
    3. Kim K,
    4. Lee E,
    5. Lee K,
    6. Ahn KH,
    7. Park H, et al.

    Prediction of TKI response in EGFR-mutant lung cancer patients-derived organoids using malignant pleural effusion. NPJ Precis Oncol. 2024; 8: 111.

    OpenUrlPubMed
68. 68.↵
    2. Chen J,
    3. Xu Q,
    4. Liu D,
    5. Li X,
    6. Guo M,
    7. Chen X, et al.

    CD146 promotes malignant progression of breast phyllodes tumor through suppressing DCBLD2 degradation and activating the AKT pathway. Cancer Commun (Lond). 2023; 43: 1244–66.

    OpenUrlPubMed
69. 69.↵
    2. Wang M,
    3. Wisniewski CA,
    4. Xiong C,
    5. Chhoy P,
    6. Goel HL,
    7. Kumar A, et al.

    Therapeutic blocking of VEGF binding to neuropilin-2 diminishes PD-L1 expression to activate antitumor immunity in prostate cancer. Sci Transl Med. 2023; 15: eade5855.
70. 70.↵
    2. Abril-Fornaguera J,
    3. Torrens L,
    4. Andreu-Oller C,
    5. Carrillo-Reixach J,
    6. Rialdi A,
    7. Balaseviciute U, et al.

    Identification of IGF2 as genomic driver and actionable therapeutic target in hepatoblastoma. Mol Cancer Ther. 2023; 22: 485–98.

    OpenUrlCrossRefPubMed
71. 71.↵
    2. Qin L,
    3. Wang L,
    4. Zhang J,
    5. Zhou H,
    6. Yang Z,
    7. Wang Y, et al.

    Therapeutic strategies targeting uPAR potentiate anti-PD-1 efficacy in diffuse-type gastric cancer. Sci Adv. 2022; 8: eabn3774.
72. 72.↵
    2. Xu Z,
    3. Goel HL,
    4. Burkart C,
    5. Burman L,
    6. Chong YE,
    7. Barber AG, et al.

    Inhibition of VEGF binding to neuropilin-2 enhances chemosensitivity and inhibits metastasis in triple-negative breast cancer. Sci Transl Med. 2023; 15: eadf1128.
73. 73.↵
    2. Zheng H,
    3. Liu J,
    4. Cheng Q,
    5. Zhang Q,
    6. Zhang Y,
    7. Jiang L, et al.

    Targeted activation of ferroptosis in colorectal cancer via LGR4 targeting overcomes acquired drug resistance. Nat Cancer. 2024; 5: 572–89.

    OpenUrlPubMed
74. 74.↵
    2. Lin SC,
    3. Tsai YC,
    4. Chen YL,
    5. Lin HK,
    6. Huang YC,
    7. Lin YS, et al.

    Un-methylation of NUDT21 represses docosahexaenoic acid biosynthesis contributing to enzalutamide resistance in prostate cancer. Drug Resist Updat. 2024; 77: 101144.
75. 75.↵
    2. Liu X,
    3. Lukowski JK,
    4. Flinders C,
    5. Kim S,
    6. Georgiadis RA,
    7. Mumenthaler SM, et al.

    MALDI-MSI of immunotherapy: mapping the EGFR-targeting antibody cetuximab in 3D colon-cancer cell cultures. Anal Chem. 2018; 90: 14156–64.

    OpenUrl
76. 76.↵
    2. Budimir N,
    3. Thomas GD,
    4. Dolina JS,
    5. Salek-Ardakani S.

    Reversing T-cell exhaustion in cancer: lessons learned from PD-1/PD-L1 immune checkpoint blockade. Cancer Immunol Res. 2022; 10: 146–53.

    OpenUrlAbstract/FREE Full Text
77. 77.↵
    2. O’Meara CH,
    3. Jafri Z,
    4. Khachigian LM.

    Immune checkpoint inhibitors, small-molecule immunotherapies and the emerging role of neutrophil extracellular traps in therapeutic strategies for head and neck cancer. Int J Mol Sci. 2023; 24: 11695.
78. 78.↵
    2. Maulana TI,
    3. Teufel C,
    4. Cipriano M,
    5. Roosz J,
    6. Lazarevski L,
    7. van den Hil FE, et al.

    Breast cancer-on-chip for patient-specific efficacy and safety testing of CAR-T cells. Cell Stem Cell. 2024; 31: 989-1002.e9.

    OpenUrlPubMed
79. 79.↵
    2. Zou F,
    3. Tan J,
    4. Liu T,
    5. Liu B,
    6. Tang Y,
    7. Zhang H, et al.

    The CD39⁺ HBV surface protein-targeted CAR-T and personalized tumor-reactive CD8⁺ T cells exhibit potent anti-HCC activity. Mol Ther. 2021; 29: 1794–807.

    OpenUrlCrossRefPubMed
80. 80.↵
    2. Yu L,
    3. Li Z,
    4. Mei H,
    5. Li W,
    6. Chen D,
    7. Liu L, et al.

    Patient-derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR-T cells in vitro. Clin Transl Immunology. 2021; 10: e1248.
81. 81.↵
    2. Zhang X,
    3. Hong B,
    4. Yu W,
    5. Miao Q,
    6. Wang W,
    7. Wang Y, et al.

    Comprehensive pan-cancer analysis reveals CD70 as a promising therapeutic target and biomarker in clear cell renal cell carcinoma. Int J Biol Macromol. 2025; 307: 142079.
82. 82.↵
    2. Logun M,
    3. Wang X,
    4. Sun Y,
    5. Bagley SJ,
    6. Li N,
    7. Desai A, et al.

    Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapy. Cell Stem Cell. 2025; 32: 181-190.e4.

    OpenUrlCrossRefPubMed
83. 83.↵
    2. Wehrli M,
    3. Guinn S,
    4. Birocchi F,
    5. Kuo A,
    6. Sun Y,
    7. Larson RC, et al.

    Mesothelin CAR T cells secreting anti-FAP/anti-CD3 molecules efficiently target pancreatic adenocarcinoma and its stroma. Clin Cancer Res. 2024; 30: 1859–77.

    OpenUrlPubMed
84. 84.↵
    2. Qiao Y,
    3. Chen J,
    4. Wang X,
    5. Yan S,
    6. Tan J,
    7. Xia B, et al.

    Enhancement of CAR-T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins. Cancer Commun (Lond). 2023; 43: 788–807.

    OpenUrlPubMed
85. 85.↵
    2. Zhai Y,
    3. Li G,
    4. Pan C,
    5. Yu M,
    6. Hu H,
    7. Wang D, et al.

    The development and potent antitumor efficacy of CD44/CD133 dual-targeting IL7Rα-armored CAR-T cells against glioblastoma. Cancer Lett. 2025; 614: 217541.
86. 86.↵
    2. Li H,
    3. Harrison EB,
    4. Li H,
    5. Hirabayashi K,
    6. Chen J,
    7. Li QX, et al.

    Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migration. Nat Commun. 2022; 13: 2154.

    OpenUrlCrossRefPubMed
87. 87.↵
    2. Liang S,
    3. Zheng R,
    4. Zuo B,
    5. Li J,
    6. Wang Y,
    7. Han Y, et al.

    SMAD7 expression in CAR-T cells improves persistence and safety for solid tumors. Cell Mol Immunol. 2024; 21: 213–26.

    OpenUrlPubMed
88. 88.↵
    2. Li YJ,
    3. Chien SH,
    4. Huang R,
    5. Herrmann A,
    6. Zhao Q,
    7. Li PC, et al.

    A platform to deliver single and bi-specific Cas9/guide RNA to perturb genes in vitro and in vivo. Mol Ther. 2024; 32: 3629–49.

    OpenUrlPubMed
89. 89.↵
    2. Wang Z,
    3. McWilliams-Koeppen HP,
    4. Reza H,
    5. Ostberg JR,
    6. Chen W,
    7. Wang X, et al.

    3D-organoid culture supports differentiation of human CAR⁺ iPSCs into highly functional CAR T cells. Cell Stem Cell. 2022; 29: 515-27.e8.

    OpenUrlCrossRefPubMed
90. 90.↵
    2. Zhu G,
    3. Sun Z,
    4. Liu Y,
    5. Liu J,
    6. Guo L,
    7. Pei G, et al.

    Rational design and organoid-based evaluation of a cocktail CAR-γδ T cell therapy for heterogeneous glioblastoma. Adv Sci (Weinh). 2025; 12: e2501772.
91. 91.↵
    2. Reddy NR,
    3. Maachi H,
    4. Xiao Y,
    5. Simic MS,
    6. Yu W,
    7. Tonai Y, et al.

    Engineering synthetic suppressor T cells that execute locally targeted immunoprotective programs. Science. 2024; 386: eadl4793.
92. 92.↵
    2. Küçükköse E,
    3. Heesters BA,
    4. Villaudy J,
    5. Verheem A,
    6. Cercel M,
    7. van Hal S, et al.

    Modeling resistance of colorectal peritoneal metastases to immune checkpoint blockade in humanized mice. J Immunother Cancer. 2022; 10: e005345.
93. 93.↵
    2. Ou L,
    3. Wang H,
    4. Huang H,
    5. Zhou Z,
    6. Lin Q,
    7. Guo Y, et al.

    Preclinical platforms to study therapeutic efficacy of human γδ T cells. Clin Transl Med. 2022; 12: e814.
94. 94.↵
    2. An HW,
    3. Seok SH,
    4. Kwon JW,
    5. Choudhury AD,
    6. Oh JS,
    7. Voon DC, et al.

    The loss of epithelial Smad4 drives immune evasion via CXCL1 while displaying vulnerability to combinatorial immunotherapy in gastric cancer. Cell Rep. 2022; 41: 111878.
95. 95.↵
    2. Wan C,
    3. Keany MP,
    4. Dong H,
    5. Al-Alem LF,
    6. Pandya UM,
    7. Lazo S, et al.

    Enhanced efficacy of simultaneous Pd-1 and PD-L1 immune checkpoint blockade in high-grade serous ovarian cancer. Cancer Res. 2021; 81: 158–73.

    OpenUrlAbstract/FREE Full Text
96. 96.↵
    2. Hamdan F,
    3. Ylösmäki E,
    4. Chiaro J,
    5. Giannoula Y,
    6. Long M,
    7. Fusciello M, et al.

    Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids. J Immunother Cancer. 2021; 9: e003000.
97. 97.↵
    2. Shiri AM,
    3. Zhang T,
    4. Bedke T,
    5. Zazara DE,
    6. Zhao L,
    7. Lücke J, et al.

    IL-10 dampens antitumor immunity and promotes liver metastasis via PD-L1 induction. J Hepatol. 2024; 80: 634–44.

    OpenUrlPubMed
98. 98.↵
    2. Sun Y,
    3. Revach OY,
    4. Anderson S,
    5. Kessler EA,
    6. Wolfe CH,
    7. Jenney A, et al.

    Targeting TBK1 to overcome resistance to cancer immunotherapy. Nature. 2023; 615: 158–67.

    OpenUrlCrossRefPubMed
99. 99.↵
    2. Koikawa K,
    3. Kibe S,
    4. Suizu F,
    5. Sekino N,
    6. Kim N,
    7. Manz TD, et al.

    Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. Cell. 2021; 184: 4753-71.e27.

    OpenUrlCrossRefPubMed
100. 100.↵
     2. Sui Q,
     3. Zhang X,
     4. Chen C,
     5. Tang J,
     6. Yu J,
     7. Li W, et al.

     Inflammation promotes resistance to immune checkpoint inhibitors in high microsatellite instability colorectal cancer. Nat Commun. 2022; 13: 7316.

     OpenUrlPubMed
101. 101.↵
     2. Gao Y,
     3. Bi D,
     4. Xie R,
     5. Li M,
     6. Guo J,
     7. Liu H, et al.

     Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer. Signal Transduct Target Ther. 2021; 6: 398.

     OpenUrlPubMed
102. 102.↵
     2. Tian J,
     3. Chen JH,
     4. Chao SX,
     5. Pelka K,
     6. Giannakis M,
     7. Hess J, et al.

     Combined PD-1, BRAF and MEK inhibition in BRAF^V600E colorectal cancer: a phase 2 trial. Nat Med. 2023; 29: 458–66.

     OpenUrlCrossRefPubMed
103. 103.↵
     2. Ebert MP,
     3. Meindl-Beinker NM,
     4. Gutting T,
     5. Maenz M,
     6. Betge J,
     7. Schulte N, et al.

     Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial. Lancet Healthy Longev. 2022; 3: e417–27.

     OpenUrl
104. 104.↵
     2. Lin W,
     3. Zhang Y,
     4. Yang Y,
     5. Lin B,
     6. Zhu M,
     7. Xu J, et al.

     Anti-PD-1/HER2 bispecific antibody IBI315 enhances the treatment effect of Her2-positive gastric cancer through gasdermin B-cleavage induced pyroptosis. Adv Sci (Weinh). 2023; 10: e2303908.
105. 105.↵
     2. Sun L,
     3. Kang X,
     4. Ju H,
     5. Wang C,
     6. Yang G,
     7. Wang R, et al.

     A human mucosal melanoma organoid platform for modeling tumor heterogeneity and exploring immunotherapy combination options. Sci Adv. 2023; 9: eadg6686.
106. 106.↵
     2. Liu C,
     3. Li K,
     4. Sui X,
     5. Zhao T,
     6. Zhang T,
     7. Chen Z, et al.

     Patient-derived tumor organoids combined with function-associated ScRNA-Seq for dissecting the local immune response of lung cancer. Adv Sci (Weinh). 2024; 11: e2400185.
107. 107.↵
     2. Hai J,
     3. Zhang H,
     4. Zhou J,
     5. Wu Z,
     6. Chen T,
     7. Papadopoulos E, et al.

     Generation of genetically engineered mouse lung organoid models for squamous cell lung cancers allows for the study of combinatorial immunotherapy. Clin Cancer Res. 2020; 26: 3431–42.

     OpenUrlAbstract/FREE Full Text
108. 108.↵
     2. Li Y,
     3. Wang M,
     4. Peng X,
     5. Yang Y,
     6. Chen Q,
     7. Liu J, et al.

     mRNA vaccine in cancer therapy: current advance and future outlook. Clin Transl Med. 2023; 13: e1384.
109. 109.↵
     2. Wang W,
     3. Yuan T,
     4. Ma L,
     5. Zhu Y,
     6. Bao J,
     7. Zhao X, et al.

     Hepatobiliary tumor organoids reveal HLA class I neoantigen landscape and antitumoral activity of neoantigen peptide enhanced with immune checkpoint inhibitors. Adv Sci (Weinh). 2022; 9: e2105810.
110. 110.↵
     2. Demmers LC,
     3. Kretzschmar K,
     4. Van Hoeck A,
     5. Bar-Epraïm YE,
     6. van den Toorn HWP,
     7. Koomen M, et al.

     Single-cell derived tumor organoids display diversity in HLA class I peptide presentation. Nat Commun. 2020; 11: 5338.

     OpenUrlCrossRefPubMed
111. 111.↵
     2. Parikh AY,
     3. Masi R,
     4. Gasmi B,
     5. Hanada KI,
     6. Parkhurst M,
     7. Gartner J, et al.

     Using patient-derived tumor organoids from common epithelial cancers to analyze personalized T-cell responses to neoantigens. Cancer Immunol Immunother. 2023; 72: 3149–62.

     OpenUrlPubMed
112. 112.↵
     2. Ren Y,
     3. Manoharan T,
     4. Liu B,
     5. Cheng CZM,
     6. En Siew B,
     7. Cheong WK, et al.

     Circular RNA as a source of neoantigens for cancer vaccines. J Immunother Cancer. 2024; 12: e008402.
113. 113.↵
     2. Newey A,
     3. Griffiths B,
     4. Michaux J,
     5. Pak HS,
     6. Stevenson BJ,
     7. Woolston A, et al.

     Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment. J Immunother Cancer. 2019; 7: 309.

     OpenUrlAbstract/FREE Full Text
114. 114.↵
     2. Liu T,
     3. Tan J,
     4. Wu M,
     5. Fan W,
     6. Wei J,
     7. Zhu B, et al.

     High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39⁺CD8⁺ T cells. Gut. 2021; 70: 1965–77.

     OpenUrlAbstract/FREE Full Text
115. 115.↵
     2. Song Y,
     3. Kerr TD,
     4. Sanders C,
     5. Dai L,
     6. Baxter SS,
     7. Somerville B, et al.

     Organoids and metastatic orthotopic mouse model for mismatch repair-deficient colorectal cancer. Front Oncol. 2023; 13: 1223915.
116. 116.↵
     2. Wu Y,
     3. Li K,
     4. Li Y,
     5. Sun T,
     6. Liu C,
     7. Dong C, et al.

     Grouped-seq for integrated phenotypic and transcriptomic screening of patient-derived tumor organoids. Nucleic Acids Res. 2022; 50: e28.
117. 117.↵
     2. Krieger TG,
     3. Tirier SM,
     4. Park J,
     5. Jechow K,
     6. Eisemann T,
     7. Peterziel H, et al.

     Modeling glioblastoma invasion using human brain organoids and single-cell transcriptomics. Neuro Oncol. 2020; 22: 1138–49.

     OpenUrlCrossRefPubMed
118. 118.↵
     2. Yao L,
     3. Hatami M,
     4. Ma W,
     5. Skutella T.

     Vaccine-based immunotherapy and related preclinical models for glioma. Trends Mol Med. 2024; 30: 965–81.

     OpenUrlPubMed
119. 119.↵
     2. Zhao B,
     3. Kilian M,
     4. Bunse T,
     5. Platten M,
     6. Bunse L.

     Tumor-reactive T helper cells in the context of vaccination against glioma. Cancer Cell. 2023; 41: 1829–34.

     OpenUrlPubMed
120. 120.↵
     2. Hilf N,
     3. Kuttruff-Coqui S,
     4. Frenzel K,
     5. Bukur V,
     6. Stevanović S,
     7. Gouttefangeas C, et al.

     Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 2019; 565: 240–5.

     OpenUrlCrossRefPubMed
121. 121.↵
     2. Qin H,
     3. Chen J,
     4. Bouchekioua-Bouzaghou K,
     5. Meng YM,
     6. Griera JB,
     7. Jiang X, et al.

     Immunization with a multi-antigen targeted DNA vaccine eliminates chemoresistant pancreatic cancer by disrupting tumor-stromal cell crosstalk. J Transl Med. 2023; 21: 702.

     OpenUrlPubMed
122. 122.↵
     2. Huang L,
     3. Rong Y,
     4. Tang X,
     5. Yi K,
     6. Qi P,
     7. Hou J, et al.

     Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer. Mol Cancer. 2022; 21: 45.

     OpenUrlPubMed
123. 123.↵
     2. Shang L,
     3. Jiang X,
     4. Zhao X,
     5. Huang X,
     6. Wang X,
     7. Jiang X, et al.

     Mitochondrial DNA-boosted dendritic cell-based nanovaccination triggers antitumor immunity in lung and pancreatic cancers. Cell Rep Med. 2024; 5: 101648.
124. 124.↵
     2. Duan Y,
     3. Xu Y,
     4. Dou Y,
     5. Xu D.

     Helicobacter pylori and gastric cancer: mechanisms and new perspectives. J Hematol Oncol. 2025; 18: 10.

     OpenUrlPubMed
125. 125.↵
     2. Suarez G,
     3. Romero-Gallo J,
     4. Piazuelo MB,
     5. Sierra JC,
     6. Delgado AG,
     7. Washington MK, et al.

     Nod1 imprints inflammatory and carcinogenic responses toward the gastric pathogen Helicobacter pylori. Cancer Res. 2019; 79: 1600–11.

     OpenUrlAbstract/FREE Full Text
126. 126.↵
     2. Holokai L,
     3. Chakrabarti J,
     4. Broda T,
     5. Chang J,
     6. Hawkins JA,
     7. Sundaram N, et al.

     Increased programmed death-ligand 1 is an early epithelial cell response to helicobacter pylori infection. PLoS Pathog. 2019; 15: e1007468.